Arax Advisory Partners
BCYC icon

Arax Advisory Partners’s Bicycle Therapeutics BCYC Stock Holding History

Arax Advisory Partners’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29K Buy
+304
New +$1.39K ﹤0.01% 4897
2026
Q1 		– Sell
-29
Closed -$205 – 3831
2025
Q4 		$205 Buy
+29
New +$214 ﹤0.01% 3713

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Arax Advisory Partners's BCYC Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Bicycle Therapeutics (BCYC) in Q2 2026: 304 shares worth $1.29K. The stake represents ﹤0.01% of the portfolio and ranks #4897 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in BCYC as recently as Q4 2025.

Arax Advisory Partners first reported a position in BCYC in Q4 2025 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Arax Advisory Partners held 304 shares of Bicycle Therapeutics worth $1.29K as of Q2 2026.
  • Bicycle Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Bicycle Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4897 holding.
  • Arax Advisory Partners first reported a position in Bicycle Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.